Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AlloNK1
- Development stage
- Unknown
- Lead developer
- Singapore General Hospital
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
AlloNK1 is an allogeneic natural killer (NK) cell therapy developed by the Singapore General Hospital for the treatment of high-risk, advanced-stage nasopharyngeal carcinoma (NPC). The therapy consists of NK cells that are enriched and expanded ex vivo from the peripheral blood mononuclear cells (PBMCs) of healthy donors within a GMP-compliant facility. AlloNK1 is designed to enhance the host's anti-tumor immune response, particularly in patients with EBV-associated NPC who exhibit detectable plasma EBV-DNA following standard treatment. In clinical settings, it is administered as an intravenous infusion in combination with concurrent chemoradiotherapy (CRT) to target residual disease and reduce the risk of recurrence.
- Other names
- Allogenic expanded Natural Killer CellsAllogeneic NK cellsAlloNK1-Singapore General Hospital-nasopharyngeal carcinomaAlloNK-1-Singapore General Hospital-nasopharyngeal carcinomaAlloNK 1-Singapore General Hospital-nasopharyngeal carcinoma
Beyond the preview
Go deeper on AlloNK1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AlloNK1.